Objective:

The article examines the objective, findings, and clinical context described in Semaglutide outcomes in Japanese patients with MASH align with results from the overall ESSENCE trial population.

Approach:

• Study population: The subgroup analysis included 116 Japanese participants among the first 800 randomized ESSENCE participants: 78 received once-weekly semaglutide 2.4 mg and 38 received placebo.
• Participant characteristics: Japanese participants had a lower mean BMI than the overall population (29.8 vs 34.3 kg/m²) and were older; 21.8% had BMI <25 kg/m².

Key Findings:

• MASH resolution without worsening fibrosis occurred in 63.1% of Japanese participants receiving semaglutide and 36.8% receiving placebo, similar to overall ESSENCE rates of 62.9% and 34.3%.
• Semaglutide numerically favored MASH resolution across BMI categories, including BMI <27 kg/m² (57.1% vs 26.7%).
• Fibrosis improvement without worsening steatohepatitis occurred in 36.5% with semaglutide; the treatment difference was imprecise amid a relatively high placebo response and small sample.
• Liver enzymes and noninvasive assessments improved, and the safety profile was broadly consistent with the global trial.
• Percentage weight loss was comparable in Japanese and overall participants (11.4% vs 10.5%), despite lower baseline body weight in the Japanese subgroup.

Interpretation:

The authors report that MASH resolution results in Japanese participants were comparable to those in the overall ESSENCE population despite differences in age and BMI. They discuss weight loss and broader metabolic effects as possible contributors; proposed direct liver effects are based on animal studies and have not been confirmed in humans.

Limitations:

• The Japanese subgroup was small, and BMI- and age-stratified analyses were exploratory with smaller numbers.
• Efficacy in non-obese participants with BMI <25 kg/m² has not been established; the lowest reported BMI category was <27 kg/m².
• Larger cohorts and longer follow-up are needed to assess liver-related events and identify predictors of response.

Conclusion:

The subgroup analysis provides evidence that the global ESSENCE MASH-resolution findings also apply to Japanese participants, while further research is needed to clarify efficacy in specific BMI groups and long-term outcomes.

Sources:

• Semaglutide for MASH in Japanese patients: findings consistent with the overall ESSENCE population